Source: Unsplash 

Koninklijke Philips NV (PHG) reported second-quarter FY21 sales growth of 6% year-on-year to €4.23 billion.

Comparable sales grew 9% Y/Y, representing double-digit growth in the Personal Health businesses and Diagnosis & Treatment businesses, partly offset by a double-digit decline in the Connected Care businesses.

The comparable order intake decreased by 15%, with double-digit growth in the Diagnosis & Treatment businesses, which was more than offset by a double-digit decline in the Connected Care businesses.

The Diagnosis & Treatment businesses posted 16% comparable sales growth Y/Y with double-digit growth in all businesses. The comparable order intake rose 29% Y/Y, with strong double-digit growth in Image-Guided Therapy, Ultrasound, and Diagnostic Imaging. The adjusted EBITDA for the segment was 13.2%.

The comparable sales in the Connected Care businesses declined 16% Y/Y. The adjusted EBITDA was 11.3%.

The Personal Health businesses recorded a comparable sales growth of 33% Y/Y, driven by double-digit growth across every business. The adjusted EBITDA was 17%.

The consolidated adjusted EBITA expanded 280 basis points to 12.6%, driven by sales growth and productivity measures. It recorded an EPS of €0.16. The adjusted EBITDA expanded 210 basis points to 18%. Philips generated €332 million in operating cash flow. It held €1 billion in cash and equivalents. The company launched a €1.5 billion share buyback program.

Outlook: Philips’ FY21financial outlook remains within its guided range for low-to-mid-single-digit comparable sales growth. Adjusted EBITA margin improvement of 60 basis points, versus prior outlook for improvement of 60-80 basis points.

Price action: PHG shares traded lower by 4.13% at $45.96 in the premarket session on the last check Monday.